# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of ...
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenu...
Atea Pharmaceuticals Inc (NASDAQ: AVIR) reported initial data from the first 52 patients in the lead-in cohort of its Phase 2 c...
A 98% Sustained Virologic Response at Week 4 (SVR4) Post-Treatment Observed in Initial Data From 52 Patients in Lead-In Cohort ...
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=976523
Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of ...